Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Head & Neck 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Urinary Bladder Neoplasms 2Urethral Neoplasms 1Ureteral Neoplasms 1Stroke 1Stomach Neoplasms 1Pulmonary Disease, Chronic Obstructive 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Nasopharyngeal Neoplasms 1Mesothelioma 1Melanoma 1Lung Neoplasms 1Liver Neoplasms 1Kidney Neoplasms 1Kidney Failure, Chronic 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Diabetes Mellitus 1Coronary Artery Disease 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1COVID-19 1Breast Neoplasms 1

Interventions

pembrolizumab 9Nivolumab 5tislelizumab 2spartalizumab 2belinostat 2atezolizumab 2Pemetrexed 2Paclitaxel 2Ipilimumab 2Fluorodeoxyglucose F18 2Docetaxel 2Cisplatin 2tocilizumab 1sargramostim 1obinutuzumab 1niraparib 1naptumomab estafenatox 1milademetan 1epacadostat 1enzalutamide 1durvalumab 1cabozantinib 1bosutinib 1Sorafenib 1Sirolimus 1Quality of Life 1Plicamycin 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Immunotherapy, Adoptive 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mesothelioma × tocilizumab × Genitourinary × Clear all
NCT05070247 2026-01-22

A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

Takeda

Phase 1/2 Terminated
61 enrolled 29 charts
BreastGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Kidney Neoplasms, Liver Neoplasms, Mesothelioma, Nasopharyngeal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡